DLBCL中Paracaspase表达与肿瘤细胞免疫表型及临床病理特征的关系  

Relationship between the expression of Paracaspase and some immunophenotypesand clincopathological features in diffuse large B-cell lymphoma

作　　者：陈玉梅[1] 郭宏伟[1] 杨文秀[1] 钟愉[2] 刘启兰[1] 

机构地区：[1]贵阳医学院,贵阳550004 [2]贵阳医学院附属医院

出　　处：《山东医药》2009年第44期10-12,共3页Shandong Medical Journal

基　　金：贵州省卫生厅科技计划项目(G2005-2);贵州省省长基金资助项目(S2004-18);贵阳医学院附属医院博士启动基金;院博士启动基金(C2005-1);贵阳医学院2009年研究生教育创新基地专项经费(S200906)。

摘　　要：目的探讨弥漫大B细胞淋巴瘤(DLBCL)中Paracaspase蛋白表达与肿瘤细胞免疫表型、临床病理特征和预后的关系。方法应用免疫组织化学S-P法检查45例DLBCL细胞的CD10、Bcl-6、MUM1和Paracaspase等蛋白的表达,收集所有病例临床病理资料并随访,对检查结果进行统计学分析。结果Paracaspase蛋白表达阳性率为53.33%,Paracaspase(+)组病例临床分期明显早于Paracaspase(-)组,Paracaspase(+)组生存状况有好于Para-caspase(-)组的趋势。结论DLBCL细胞出现Paracaspase蛋白可能预示患者有一个较好的临床过程和生存状况。Objective To investigate the relationship between the expression of Paracaspase and some immunophenotypes, clinicopathologieal features in diffuse large B cell lymphoma （DLBCL）. Methods Expression of some immunophenotypes neoplastic cells, such as CD10, Bcl-6, MUM1, Paracaspase, etc, in DLBCL, were measured by immumohistochemistry stain. The clinicopathological data of all cases were collected to analyse. Results The positive rate of Paracaspase expression was 53.33% , the clinic stage was earlier in postive Paracaspase group than negative group, and a better trend of survival status was noticed in postive Paracaspase group. Conclusion The expression of Paracaspase may be associated with a better clinical course and prognosis in DLBCL.

关 键 词：淋巴瘤 Paracaspase 免疫表型分型 病理学 临床 

分 类 号：R733.4[医药卫生—肿瘤]